Research programme: metabotropic glutamate receptor positive allosteric modulators - Domain Therapeutics

Drug Profile

Research programme: metabotropic glutamate receptor positive allosteric modulators - Domain Therapeutics

Alternative Names: DT 1687; DT 2208; DT2228; mGluR PAM - Domain Therapeutics; mGluR2 PAM; mGluR3 PAM; mGluR4 PAMs

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Faust Pharmaceuticals
  • Developer Domain Therapeutics; Prexton Therapeutics
  • Class Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators; Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Parkinson's disease
  • No development reported Anxiety disorders
  • Discontinued Pain; Schizophrenia

Most Recent Events

  • 22 Oct 2016 Research development is ongoing in Parkinson's disease in France (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Anxiety-disorders in France (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top